tiprankstipranks
Glaukos Corp. (GKOS)
NYSE:GKOS
US Market
GKOS
Glaukos
RESEARCH TOOLSreports
Want to see GKOS full AI Analyst Report?

Glaukos (GKOS) Stock Forecast & Price Target

423 Followers
See the Price Targets and Ratings of:

GKOS Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Glaukos
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GKOS Stock 12 Month Forecast

Average Price Target

$163.00
▲(30.62% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Glaukos in the last 3 months. The average price target is $163.00 with a high forecast of $180.00 and a low forecast of $138.00. The average price target represents a 30.62% change from the last price of $124.79.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"82":"$82","181":"$181","106.75":"$106.8","131.5":"$131.5","156.25":"$156.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":163,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$163.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":138,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$138.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[82,106.75,131.5,156.25,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,137.57,140.83384615384614,144.0976923076923,147.36153846153846,150.6253846153846,153.88923076923078,157.15307692307692,160.41692307692307,163.68076923076922,166.9446153846154,170.20846153846153,173.4723076923077,176.73615384615385,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,137.57,139.52615384615385,141.4823076923077,143.43846153846152,145.39461538461538,147.35076923076923,149.30692307692308,151.2630769230769,153.21923076923076,155.17538461538462,157.13153846153847,159.0876923076923,161.04384615384615,{"y":163,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,137.57,137.6030769230769,137.63615384615383,137.66923076923075,137.7023076923077,137.73538461538462,137.76846153846154,137.80153846153846,137.83461538461538,137.8676923076923,137.90076923076924,137.93384615384616,137.96692307692308,{"y":138,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":102.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.91,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.47,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.12,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.64,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.22,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.12,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.57,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$180.00Average Price Target$163.00Lowest Price Target$138.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on GKOS
Thomas Stephan
Stifel Nicolaus
Stifel Nicolaus
$170→$175
Buy
40.24%
Upside
Assigned
07/17/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Truist Financial Analyst forecast on GKOS
Richard Newitter
Truist Financial
Truist Financial
$160→$180
Buy
44.24%
Upside
Reiterated
07/16/26
Glaukos price target raised to $180 from $160 at TruistGlaukos price target raised to $180 from $160 at Truist
BTIG Analyst forecast on GKOS
Ryan Zimmerman
BTIG
BTIG
$162→$164
Buy
31.42%
Upside
Assigned
07/13/26
Glaukos price target raised to $164 from $162 at BTIGGlaukos price target raised to $164 from $162 at BTIG
Citi Analyst forecast on GKOS
Joanne Wuensch
Citi
Citi
$162→$175
Buy
40.24%
Upside
Reiterated
07/08/26
Citi Sticks to Its Buy Rating for Glaukos (GKOS)
William Blair Analyst forecast on GKOS
Steven Lichtman
William Blair
William Blair
―
Buy
―
Reiterated
07/06/26
Glaukos: Favorable iDose Reimbursement Outlook and Epioxa Launch Drive Attractive Risk-Reward, Supporting Buy Rating
H.C. Wainwright Analyst forecast on GKOS
Yi Chen
H.C. Wainwright
H.C. Wainwright
$168
Buy
34.63%
Upside
Initiated
07/06/26
Glaukos initiated with a Buy at H.C. WainwrightGlaukos initiated with a Buy at H.C. Wainwright
Piper Sandler Analyst forecast on GKOS
Adam Maeder
Piper Sandler
Piper Sandler
$165
Buy
32.22%
Upside
Reiterated
07/01/26
Analysts Conflicted on These Healthcare Names: Alumis Inc. (NASDAQ: ALMS), Glaukos (NYSE: GKOS) and Regeneron (NASDAQ: REGN)
Jefferies Analyst forecast on GKOS
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$165
Buy
32.22%
Upside
Reiterated
06/23/26
Jefferies Remains a Buy on Glaukos (GKOS)
Needham Analyst forecast on GKOS
David Saxon
Needham
Needham
$136→$150
Buy
20.20%
Upside
Reiterated
06/17/26
Analysts Conflicted on These Healthcare Names: Simulations Plus (NASDAQ: SLP), Incyte (NASDAQ: INCY) and Glaukos (NYSE: GKOS)
J.P. Morgan Analyst forecast on GKOS
Allen Gong
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/05/26
Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA) and Glaukos (NYSE: GKOS)
Wells Fargo Analyst forecast on GKOS
Larry Biegelsen
Wells Fargo
Wells Fargo
$138
Buy
10.59%
Upside
Reiterated
06/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pfizer (NYSE: PFE), Dexcom (NASDAQ: DXCM) and Glaukos (NYSE: GKOS)
Goldman Sachs Analyst forecast on GKOS
David Roman
Goldman Sachs
Goldman Sachs
$153
Buy
22.61%
Upside
Reiterated
05/25/26
Goldman Sachs Reaffirms Their Buy Rating on Glaukos (GKOS)
Mizuho Securities Analyst forecast on GKOS
Anthony Petrone
Mizuho Securities
Mizuho Securities
$130→$160
Buy
28.22%
Upside
Reiterated
04/30/26
Glaukos (GKOS) Receives a Buy from Mizuho Securities
Morgan Stanley Analyst forecast on GKOS
Patrick Wood
Morgan Stanley
Morgan Stanley
$72
Sell
-42.30%
Downside
Reiterated
02/20/26
Morgan Stanley Remains a Sell on Glaukos (GKOS)
UBS Analyst forecast on GKOS
Danielle Antalffy
UBS
UBS
$145→$150
Buy
20.20%
Upside
Reiterated
01/28/26
UBS Keeps Their Buy Rating on Glaukos (GKOS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on GKOS
Thomas Stephan
Stifel Nicolaus
Stifel Nicolaus
$170→$175
Buy
40.24%
Upside
Assigned
07/17/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Truist Financial Analyst forecast on GKOS
Richard Newitter
Truist Financial
Truist Financial
$160→$180
Buy
44.24%
Upside
Reiterated
07/16/26
Glaukos price target raised to $180 from $160 at TruistGlaukos price target raised to $180 from $160 at Truist
BTIG Analyst forecast on GKOS
Ryan Zimmerman
BTIG
BTIG
$162→$164
Buy
31.42%
Upside
Assigned
07/13/26
Glaukos price target raised to $164 from $162 at BTIGGlaukos price target raised to $164 from $162 at BTIG
Citi Analyst forecast on GKOS
Joanne Wuensch
Citi
Citi
$162→$175
Buy
40.24%
Upside
Reiterated
07/08/26
Citi Sticks to Its Buy Rating for Glaukos (GKOS)
William Blair Analyst forecast on GKOS
Steven Lichtman
William Blair
William Blair
―
Buy
―
Reiterated
07/06/26
Glaukos: Favorable iDose Reimbursement Outlook and Epioxa Launch Drive Attractive Risk-Reward, Supporting Buy Rating
H.C. Wainwright Analyst forecast on GKOS
Yi Chen
H.C. Wainwright
H.C. Wainwright
$168
Buy
34.63%
Upside
Initiated
07/06/26
Glaukos initiated with a Buy at H.C. WainwrightGlaukos initiated with a Buy at H.C. Wainwright
Piper Sandler Analyst forecast on GKOS
Adam Maeder
Piper Sandler
Piper Sandler
$165
Buy
32.22%
Upside
Reiterated
07/01/26
Analysts Conflicted on These Healthcare Names: Alumis Inc. (NASDAQ: ALMS), Glaukos (NYSE: GKOS) and Regeneron (NASDAQ: REGN)
Jefferies Analyst forecast on GKOS
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$165
Buy
32.22%
Upside
Reiterated
06/23/26
Jefferies Remains a Buy on Glaukos (GKOS)
Needham Analyst forecast on GKOS
David Saxon
Needham
Needham
$136→$150
Buy
20.20%
Upside
Reiterated
06/17/26
Analysts Conflicted on These Healthcare Names: Simulations Plus (NASDAQ: SLP), Incyte (NASDAQ: INCY) and Glaukos (NYSE: GKOS)
J.P. Morgan Analyst forecast on GKOS
Allen Gong
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/05/26
Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA) and Glaukos (NYSE: GKOS)
Wells Fargo Analyst forecast on GKOS
Larry Biegelsen
Wells Fargo
Wells Fargo
$138
Buy
10.59%
Upside
Reiterated
06/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pfizer (NYSE: PFE), Dexcom (NASDAQ: DXCM) and Glaukos (NYSE: GKOS)
Goldman Sachs Analyst forecast on GKOS
David Roman
Goldman Sachs
Goldman Sachs
$153
Buy
22.61%
Upside
Reiterated
05/25/26
Goldman Sachs Reaffirms Their Buy Rating on Glaukos (GKOS)
Mizuho Securities Analyst forecast on GKOS
Anthony Petrone
Mizuho Securities
Mizuho Securities
$130→$160
Buy
28.22%
Upside
Reiterated
04/30/26
Glaukos (GKOS) Receives a Buy from Mizuho Securities
Morgan Stanley Analyst forecast on GKOS
Patrick Wood
Morgan Stanley
Morgan Stanley
$72
Sell
-42.30%
Downside
Reiterated
02/20/26
Morgan Stanley Remains a Sell on Glaukos (GKOS)
UBS Analyst forecast on GKOS
Danielle Antalffy
UBS
UBS
$145→$150
Buy
20.20%
Upside
Reiterated
01/28/26
UBS Keeps Their Buy Rating on Glaukos (GKOS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ENOVEnovis
GKOSGlaukos
IMUXImmunic
AVTXAvalo Therapeutics
TARAProtara Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Glaukos

3 Months
Adam MaederPiper Sandler
Success Rate
12/13 ratings generated profit
92%
Average Return
+14.87%
Copying Adam Maeder's trades and holding each position for 3 Months would result in 92.31% of your transactions generating a profit, with an average return of +14.87% per trade.
1 Year
Adam MaederPiper Sandler
Success Rate
13/13 ratings generated profit
100%
Average Return
+47.82%
Copying Adam Maeder's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +47.82% per trade.
2 Years
David SaxonNeedham
Success Rate
23/23 ratings generated profit
100%
Average Return
+61.77%
Copying David Saxon's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +61.77% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GKOS Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
3
2
2
0
0
Buy
27
23
24
32
28
Hold
0
0
0
0
0
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
31
26
26
32
28
In the current month, GKOS has received 28 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GKOS average Analyst price target in the past 3 months is 163.00.
Each month's total comprises the sum of three months' worth of ratings.

GKOS Financial Forecast

GKOS Earnings Forecast

Next quarter’s earnings estimate for GKOS is -$0.22 with a range of -$0.31 to -$0.12. The previous quarter’s EPS was -$0.18. GKOS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year GKOS has Performed in-line its overall industry.
Next quarter’s earnings estimate for GKOS is -$0.22 with a range of -$0.31 to -$0.12. The previous quarter’s EPS was -$0.18. GKOS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year GKOS has Performed in-line its overall industry.

GKOS Sales Forecast

Next quarter’s sales forecast for GKOS is $150.99M with a range of $147.50M to $156.80M. The previous quarter’s sales results were $150.57M. GKOS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year GKOS has Performed in-line its overall industry.
Next quarter’s sales forecast for GKOS is $150.99M with a range of $147.50M to $156.80M. The previous quarter’s sales results were $150.57M. GKOS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year GKOS has Performed in-line its overall industry.

GKOS Stock Forecast FAQ

What is GKOS’s average 12-month price target, according to analysts?
Based on analyst ratings, Glaukos Corp.’s 12-month average price target is 163.00.
    What is GKOS’s upside potential, based on the analysts’ average price target?
    Glaukos Corp. has 30.62% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GKOS a Buy, Sell or Hold?
          Glaukos Corp. has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Glaukos Corp.’s price target?
            The average price target for Glaukos Corp. is 163.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $180.00 ,the lowest forecast is $138.00. The average price target represents 30.62% Increase from the current price of $124.79.
              What do analysts say about Glaukos Corp.?
              Glaukos Corp.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of GKOS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.